These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18520356)

  • 1. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 3. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG; van den Berk GE
    AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
    [No Abstract]   [Full Text] [Related]  

  • 4. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 6. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raltegravir: initially as effective as standard therapy].
    Warpakowski A
    MMW Fortschr Med; 2010 Apr; 152(17):49. PubMed ID: 20509262
    [No Abstract]   [Full Text] [Related]  

  • 9. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year.
    Albrecht H
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20626067
    [No Abstract]   [Full Text] [Related]  

  • 10. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
    Rowley M
    Prog Med Chem; 2008; 46():1-28. PubMed ID: 18381123
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
    [No Abstract]   [Full Text] [Related]  

  • 17. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 18. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.